AD-Smart
AD-SMART is a first-of-its-kind clinical trial testing several potential treatments for Alzheimer's disease at the same time and comparing them against a placebo. The trial begins with two medicines that are already approved and safely used for other conditions: metformin, which is currently used to treat type 2 diabetes, and atomoxetine, which is currently used to treat ADHD.
Who can take part?
You may be eligible if you:
Are aged 55 or over
Have a confirmed clinical diagnosis of Alzheimer's disease or mixed dementia consisting of Alzheimer's disease and vascular dementia
Have a family member or friend who knows you well and can attend study visits with you
Please note: This is not a complete list of eligibility criteria. Additional inclusion and exclusion criteria will be assessed by the study team during screening.
What does the trial involve?
Taking oral tablet medication involving one of two medicines:
Metformin - currently used to treat type 2 diabetes
Atomoxetine - currently used to treat ADHD
Length of trial: 18 months (for participants who successfully complete screening)
Trial type: Multi-arm, multi-stage platform trial